cp wire

CP Wire Articles

ADMA Biologics Resubmits BLA for Primary Immunodeficiency Disease Drug
  • ADMA received a CRL in July of 2016
  • The Company was able to resubmit RI-002’s BLA as a direct result of the recent improvement in compliance status for the Company’s Boca Raton, FL... read more
Mon, 10/1/18 - 10:00 am
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
  • Results from the trial demonstrated that combination treatment with Adcetris plus CHP was superior to the control arm for progression free survival (PFS)
  • All other key secondary... read more
Mon, 10/1/18 - 09:28 am
First Patient Dosed in Ph III Trial of Bemarituzumab for Advanced Gastric and Gastroesophageal Junction Cancers


Five Prime Therapeutics, Inc. (Nasdaq: FPRX) and Zai Lab Limited (Nasdaq: ZLAB) announced on 10/1/18 dosing of the first patient in the Phase 3 FIGHT pivotal trial of bemarituzumab (FPA144),... read more

Mon, 10/1/18 - 09:07 am
KSQ Therapeutics Banks $80 Million in Series C Round
  • KSQ raised $76 million in October of 2017
  • The company has 14 candidates in pre-clinical development


KSQ Therapeutics announced today that the company has secured an... read more

Fri, 09/28/18 - 11:53 am
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
  • Patisiran is approved in the US for hATTR
  • It has orphan drug status in the US and Japan
  • Patisiran is elegible for priority review in Japan


Alnylam... read more

Fri, 09/28/18 - 09:28 am

Pages